ClinicalTrials.gg
CompletedNCT01596062IDEALEUpdated Jul 25, 2014Results posted

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

A Phase 2 interventional study of Simulect® and Neoral® in Renal Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aims of this study are to extensively study the levels of CD25-Receptors saturation and expression obtained with 2 different doses of Simulect® in combination with Neoral® (i.e to demonstrate that saturation and expression vary according to the dose of Simulect® given), and to study the levels of CD25-Receptors saturation without Neoral® and compare them to the data with Neoral®.

It will be conducted in low risk de novo adult renal transplant recipients until 12 weeks post-transplant, receiving either a cumulative dose of 40 or 80 mg of Simulect® in combination with Neoral®, or a cumulative dose of 80 mg of Simulect® in a calcineurin inhibitor free immunosuppressant therapy.

02

Conditions studied

  • Renal Transplantation

Keywords

  • Basiliximab
  • renal transplantation
  • CNI-free
  • everolimus
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving a primary renal graft from a deceased or living, related or unrelated donor and who require basiliximab induction therapy
  • Cold ischemia time \< 30 hours

Exclusion criteria

Exclusion (Non inclusion) criteria:

  • Patients undergoing multi-organ transplantation, including both kidneys, or who have previously undergone organ transplantation, including renal transplantation
  • Patients receiving a graft from a non-heart-beating donor
  • A-B-O incompatible graft or positive T cell crossmatch
  • Patients receiving a graft from an expanded criteria donor according to the UNOS definition (donor older than 60 years or donor aged between 50 and 60 years and presence of at least 2 of the following factors: hypertension, serum creatinine concentration ≥ 132 µmol/mL, cardiovascular cause of death)
  • Positive anti-HLA antibodies (Luminex) prior to transplantation
  • Patients whose original renal disease was primary focal and segmental hyalinosis or was related to atypical hemolytic uremic syndrome
  • EBV-negative patients receiving a graft from an EBV-positive donor (EBV D+R-)

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    Simulect 40mg + Neoral + Myfortic + steroids

    A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids

    Drug: Simulect® · Drug: Neoral® · Drug: Myfortic® · Drug: Corticosteroids

  • Experimental
    Simulect 80mg + Neoral + Myfortic + steroids

    A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids

    Drug: Simulect® · Drug: Neoral® · Drug: Myfortic® · Drug: Corticosteroids

  • Experimental
    Simulect 80mg + Certican + Myfortic + steroids

    A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids

    Drug: Simulect® · Drug: Certican® · Drug: Myfortic® · Drug: Corticosteroids

Interventions

  • Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).

    Also known as: Basiliximab

  • Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.

    Also known as: Cyclosporine microemulsion

  • Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.

    Also known as: Everolimus

  • Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.

    Also known as: mycophenolate sodium

  • DrugCorticosteroids

    Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84

    CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.

    Time frame: Day 84 (Week 12) after transplantation

  2. Saturation Rate of CD25 Antigen Saturation by Basiliximab

    CD25 saturation is the percentage of T cells expressing CD25

    Time frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation

Secondary outcomes

  1. AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84

    Mean AUC was calculated only for patients who received two Simulect injections.

    Time frame: Day 84 (Week 12) post-transplantation

  2. Percentage of T-cells That Bind Basiliximab to CD25 Receptors

    This is the percentage of T cells binding basiliximab at all timepoints.

    Time frame: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation

  3. Proportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells

    Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry).

    Time frame: Day 0, Day 6, Day 42, Day 84 (Week 12)

  4. Percentage of Participants With of Biopsy Proven Acute Rejection (BPAR)

    BPAR is one of the components of treatment failure. One assessment of efficacy was BPAR. Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant.

    Time frame: Day 84 (Week 12), Week 24 post-transplantation

  5. Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity

    Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation. Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis. Type IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

    Time frame: Day 84 (Week 12), Week 24 post-transplantation

  6. Percentage of Participants With of Treatment Failures

    Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up. An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up. Treated borderline lesions were considered as acute rejection by investigators and DMC experts.

    Time frame: Day 84 (Week 12), Week 24

  7. Estimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24

    (MDRDa formula) with imputation by last observation carried forward (LOCF)

    Time frame: Day 8, Week 24

07

Results

Posted Jul 25, 2014

Participant flow

With premature end of recruitment only 16 patients were included. Descriptive analysis was done \& statistical method fitted the small number of patients. One final analysis was performed at M6 post-transplantation \& comprised assessment of criteria planned at M3 and M6. Some analysis pertaining to the secondary objectives were not performed.

Participant flow — Overall Study
MilestoneSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Started367
Completed264
Not completed103
Withdrew: Adverse event102
Withdrew: Lack of efficacy001

Outcome measures

PrimaryArea Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84

CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.

Time frame:
Day 84 (Week 12) after transplantation
Reported as:
Mean · Weeks * Percentage of saturated CD25
Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84
Weeks * Percentage of saturated CD25Simulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 848.4 ± 1.6111.1 ± 1.129.7 ± 0.70
PrimarySaturation Rate of CD25 Antigen Saturation by Basiliximab

CD25 saturation is the percentage of T cells expressing CD25

Time frame:
Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
Reported as:
Mean · percentage of T cells
Saturation Rate of CD25 Antigen Saturation by Basiliximab
percentage of T cellsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day 0 (before injection)0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Day 0 (2 hours after injection)93.7 ± 10.9796.7 ± 8.1694.7 ± 5.19
Day 195.7 ± 7.5197.7 ± 5.2499.0 ± 2.65
Day 4 (before injection); (n= 3, 6, 6)100.0 ± 0.0096.2 ± 6.8893.7 ± 9.89
Day 4 (2 hours after injection): (n= 3, 6, 5)96.7 ± 5.7796.3 ± 6.8384.8 ± 19.25
Day 6: (n= 3, 6, 6)98.7 ± 2.31100.0 ± 0.0094.0 ± 14.70
Day 14: (n= 3, 6, 6)98.3 ± 2.8996.7 ± 7.2397.3 ± 6.53
Day 21: (n= 3, 6, 6)100.0 ± 0.0094.5 ± 10.8092.5 ± 11.83
Day 28: (n= 3, 6, 6)95.3 ± 4.16100.0 ± 0.0092.7 ± 9.33
Day 42: (n= 3, 6, 5)78.3 ± 9.07100.0 ± 0.0099.2 ± 1.79
Day 56: (n= 3, 6, 5)65.0 ± 56.3593.3 ± 13.2094.2 ± 12.97
Day 84 (Week 12): (n= 3, 6, 5)0.0 ± 0.0067.5 ± 48.5514.2 ± 20.86
SecondaryAUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84

Mean AUC was calculated only for patients who received two Simulect injections.

Time frame:
Day 84 (Week 12) post-transplantation
Reported as:
Mean · Weeks * Percentage of T cells
AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84
Weeks * Percentage of T cellsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 847.0 ± 1.809.9 ± 2.228.4 ± 0.75
SecondaryPercentage of T-cells That Bind Basiliximab to CD25 Receptors

This is the percentage of T cells binding basiliximab at all timepoints.

Time frame:
Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation
Reported as:
Mean · Percentage of T cells
Percentage of T-cells That Bind Basiliximab to CD25 Receptors
Percentage of T cellsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day 0 (before injection)0.0 ± 0.000.0 ± 0.004.7 ± 12.47
Day 0 (2 hours after injection)95.3 ± 8.0896.2 ± 9.3981.6 ± 28.30
Day 1 (n= 3, 5, 7)70.0 ± 28.5864.8 ± 35.1591.4 ± 11.65
Day 4 (before injection): (n= 3, 6, 6)100.0 ± 0.0059.0 ± 45.9853.0 ± 33.33
Day 4 (2 hours after injection): (n= 3, 5, 5)100.0 ± 0.0083.4 ± 20.1481.2 ± 16.02
Day 6: (n= 3, 6, 6)91.7 ± 14.4399.0 ± 2.4598.3 ± 4.08
Day 14: (n= 3, 6, 6)100.0 ± 0.0089.0 ± 22.0093.8 ± 15.11
Day 21: (n= 3, 6, 6)89.0 ± 19.0587.7 ± 26.9385.8 ± 32.31
Day 28: (n= 3, 6, 6)76.3 ± 17.6291.0 ± 14.0082.7 ± 26.29
Day 42: (n= 3, 6, 5)47.3 ± 28.2284.0 ± 19.7578.8 ± 30.11
Day 56: (n= 3, 6, 5)53.0 ± 41.8088.8 ± 27.3575.2 ± 15.29
Day 84 (Week 12): (n= 3, 6, 5)6.7 ± 6.1157.7 ± 43.8315.8 ± 9.73
SecondaryProportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells

Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry).

Time frame:
Day 0, Day 6, Day 42, Day 84 (Week 12)
Reported as:
Mean · 10^9 cells/L
Proportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells
10^9 cells/LSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
CD3 cells count at Day 0 (before injection)0.5 ± 0.250.9 ± 0.280.7 ± 0.28
CD3 cells count at Day 6: (n= 3, 6, 6)0.6 ± 0.391.1 ± 0.500.9 ± 0.75
CD3 cells count at Day 42: (n= 3, 6, 5)0.5 ± 0.091.2 ± 0.961.1 ± 1.18
CD3 cells count at Day 84 (Week 12): (n= 3, 6, 6)0.8 ± 0.581.2 ± 0.721.1 ± 1.22
CD4 cells count at Day 0 (before injection)0.4 ± 0.190.6 ± 0.200.5 ± 0.22
CD4 cells count at Day 6: (n= 3, 6, 6)0.5 ± 0.300.7 ± 0.280.6 ± 0.59
CD4 cells count at Day 42: (n= 3, 6, 5)0.3 ± 0.080.8 ± 0.530.8 ± 0.82
CD4 cells count at Day 84 (Week 12): (n= 3, 6, 6)0.6 ± 0.360.8 ± 0.420.7 ± 0.86
CD8 cells count at Day 0 (before injection)0.1 ± 0.050.3 ± 0.130.2 ± 0.15
CD8 cells count at Day 6: (n= 3, 6, 6)0.2 ± 0.080.3 ± 0.250.2 ± 0.24
CD8 cells count at Day 42: (n= 3, 6, 5)0.1 ± 0.050.3 ± 0.440.4 ± 0.37
CD8 cells count at Day 84 (Week 12): (n= 3, 6, 6)0.2 ± 0.240.3 ± 0.320.3 ± 0.37
CD19 cells count at Day 0 (before injection)0.1 ± 0.080.1 ± 0.100.1 ± 0.05
CD19 cells count at Day 6: (n=3, 6, 6)0.1 ± 0.070.2 ± 0.270.2 ± 0.17
CD19 cells count at Day 42: (n= 3, 6, 5)0.1 ± 0.090.2 ± 0.210.2 ± 0.18
CD19 cells count at Day 84 (Week 12): (n= 3, 6, 6)0.2 ± 0.200.1 ± 0.110.1 ± 0.15
CD56 cells count at Day 0 (before injection)0.1 ± 0.200.2 ± 0.140.2 ± 0.31
CD56 cells count at Day 6: (n= 3, 6, 6)0.1 ± 0.000.1 ± 0.060.2 ± 0.25
CD56 cells count at Day 42: (n= 3, 6, 5)0.1 ± 0.050.2 ± 0.100.2 ± 0.13
CD56 cells count at Day 84 (Week 12): (n= 3, 6, 6)0.1 ± 0.050.1 ± 0.030.1 ± 0.15
SecondaryPercentage of Participants With of Biopsy Proven Acute Rejection (BPAR)

BPAR is one of the components of treatment failure. One assessment of efficacy was BPAR. Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant.

Time frame:
Day 84 (Week 12), Week 24 post-transplantation
Reported as:
Number · Percentage of participants
Percentage of Participants With of Biopsy Proven Acute Rejection (BPAR)
Percentage of participantsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day 84 (Week 12): No66.783.342.9
Day 84 (Week 12):Yes33.316.757.1
Week 24: No66.783.342.9
Week 24:Yes33.316.757.1
SecondaryPercentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity

Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation. Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis. Type IIB: Severe intimal arteritis comprising \> 25% of the lumenal area. Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation).

Time frame:
Day 84 (Week 12), Week 24 post-transplantation
Reported as:
Number · Percentage of participants
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity
Percentage of participantsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day 84 (Week 12): Antibody mediated AR - No66.7100.085.7
Day 84 (Week 12): Antibody mediated AR - Yes33.30.014.3
Day 84 (Week 12): Cellular AR - No100.083.357.1
Day 84 (Week 12): Cellular AR - Yes0.016.742.9
Day 84 (Week 12): Banff type lA0.00.014.3
Day 84 (Week 12): Banff type lB0.016.714.3
Day 84 (Week 12): Banff type llA0.00.00.0
Day 84 (Week 12): Banff type llB0.00.014.3
Day 84 (Week 12): Banff type lll (C AR)0.00.00.0
Week 24: Antibody mediated AR - No66.7100.085.7
Week 24: Antibody mediated AR - Yes33.30.014.3
Week 24: Cellular AR - No100.083.357.1
Week 24: Cellular AR - Yes0.016.742.9
Week 24: Banff type lA0.00.00.0
Week 24: Banff type lB0.016.728.6
Week 24: Banff type llA0.00.00.0
Week 24: Banff type llB0.00.014.3
Week 24: Banff type lll0.00.00.0
SecondaryPercentage of Participants With of Treatment Failures

Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up. An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up. Treated borderline lesions were considered as acute rejection by investigators and DMC experts.

Time frame:
Day 84 (Week 12), Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With of Treatment Failures
Percentage of participantsSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day84 (Week 12): BPAR and/or borderline lesions-No66.766.714.3
Day84 (Week 12):BPAR and/or borderline lesions-Yes33.333.385.7
Day 84 (Week 12): Graft loss - No66.7100.0100.0
Day 84 (Week 12): Graft loss - Yes33.30.00.0
Day 84 (Week 12): Death - No100.0100.0100.0
Day 84 (Week 12): Death - Yes0.00.00.0
Day 84 (Week 12): Loss to follow-up - No100.0100.0100.0
Day 84 (Week 12): Loss to follow-up - Yes0.00.00.0
Week 24: BPAR or borderline lesions - No66.766.714.3
Week 24: Graft loss - No66.7100.0100.0
Week 24: Death - No100.0100.0100.0
Week 24: Loss to follow-up - No100.0100.0100.0
Week 24: Loss to follow-up - Yes0.00.00.0
Week 24: BPAR or borderline lesions - Yes33.333.385.7
Week 24: Graft loss - Yes33.30.00.0
Week 24: Death - Yes0.00.00.0
SecondaryEstimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24

(MDRDa formula) with imputation by last observation carried forward (LOCF)

Time frame:
Day 8, Week 24
Reported as:
Mean · mL/min/1.73m^2
Estimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24
mL/min/1.73m^2Simulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Day 835.0 ± 13.2053.8 ± 23.7949.9 ± 18.45
Week 24 (n= 3, 6, 6)31.9 ± 27.9355.7 ± 15.6854.4 ± 10.48

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Simulect 40mg + Neoral + Myfortic + Steroids—2/3 (66.7%)3/3 (100%)
Simulect 80mg + Neoral + Myfortic + Steroids—2/6 (33.3%)6/6 (100%)
Simulect 80mg + Certican + Myfortic + Steroids—5/7 (71.4%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Transplant rejectionImmune system disorders1/30/61/7
Femur fractureInjury, poisoning and procedural complications1/30/60/7
Graft lossInjury, poisoning and procedural complications1/30/60/7
Post procedural haematuriaInjury, poisoning and procedural complications1/30/60/7
Renal failure acuteRenal and urinary disorders0/30/62/7
GastritisGastrointestinal disorders0/31/60/7
Blood creatinine increasedInvestigations0/31/61/7
Diabetes mellitusMetabolism and nutrition disorders0/31/60/7
CoughRespiratory, thoracic and mediastinal disorders0/31/60/7
Peritoneal haemorrhageGastrointestinal disorders0/30/61/7
Most frequent other events
Showing 10 of 56
Most frequent other events
EventSimulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + Steroids
Oedema peripheralGeneral disorders3/31/61/7
HypertensionVascular disorders2/31/64/7
Cytolytic hepatitisHepatobiliary disorders1/33/60/7
AnaemiaBlood and lymphatic system disorders1/32/62/7
NeutropeniaBlood and lymphatic system disorders0/32/60/7
ThrombocytopeniaBlood and lymphatic system disorders1/30/60/7
AscitesGastrointestinal disorders1/30/60/7
Gingival hypertrophyGastrointestinal disorders1/31/60/7
CholestasisHepatobiliary disorders1/30/60/7
Complications of transplanted kidneyInjury, poisoning and procedural complications1/30/61/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Simulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + SteroidsTotal
Mean53.7 ± 8.745.0 ± 11.439.7 ± 12.244.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Simulect 40mg + Neoral + Myfortic + SteroidsSimulect 80mg + Neoral + Myfortic + SteroidsSimulect 80mg + Certican + Myfortic + SteroidsTotal
Female0224
Male34512
08

Study locations

3 sites
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Paris cedex 15, 75015, France
  • Novartis Investigative Site
    Tours Cedex, 37044, France
09

References and documents

Publications

  • Thibault G, Paintaud G, Legendre C, Merville P, Coulon M, Chasseuil E, Ternant D, Rostaing L, Durrbach A, Di Giambattista F, Buchler M, Lebranchu Y. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. Transpl Int. 2016 Feb;29(2):184-95. doi: 10.1111/tri.12688. Epub 2015 Oct 8. PubMed 26369526 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2011
First posted
May 10, 2012
Start
Mar 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jul 25, 2014
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01596062
Responsible party
Sponsor
First posted
May 10, 2012
Start date
Mar 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jul 25, 2014
Last update
Jul 25, 2014

Study contacts

Novartis Pharmaceticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Everolimus

Start the discussion